• Journal of Ginseng Research
• /
• 제39권4호
• /
• pp.304-313
• /
• 2015

Background: Ginsenoside Rg3 is a promising anticancer agent. It is usually produced by heat treatment of ginseng, in which ginsenoside Rb1 is the major ginsenoside. A kinetic study was conducted to optimize ginsenoside Rg3 production by the heat treatment of ginsenoside Rb1. Methods: Ginsenoside Rb1 was heated using an isothermal machine at $80^{\circ}C$ and $100^{\circ}C$ and analyzed using HPLC. The kinetic parameters were calculated from the experimental results. The activation energy was estimated and used to simulate the process. The optimized parameters of ginsenoside Rg3 production are suggested based on the simulation. Results: The rate constants were $0.013h^{-1}$ and $0.073h^{-1}$ for the degradation of ginsenosides Rb1 and Rg3 at $80^{\circ}C$, respectively. The corresponding rate constants at $100^{\circ}C$ were $0.045h^{-1}$ and $0.155h^{-1}$. The estimated activation energies of degradation of ginsenosides Rb1 and Rg3 were 69.2 kJ/mol and 40.9 kJ/mol, respectively. The rate constants at different temperatures were evaluated using the estimated activation energies, and the kinetic profiles of ginsenosides Rb1 and Rg3 at each temperature were simulated based on the proposed kinetic model of consecutive reaction. The optimum strategies for producing ginsenoside Rg3 from ginsenoside Rb1 are suggested based on the simulation. With increased temperature, a high concentration of ginsenoside Rg3 is formed rapidly. However, the concentration decreases quickly after the reaching the maximal concentration value. Conclusion: The optimum temperature for producing ginsenoside Rg3 should be the highest temperature technically feasible below $180^{\circ}C$, in consideration of the cooling time. The optimum reaction time for heat treatment is 30 min.

• 식물조직배양학회지
• /
• 제27권6호
• /
• pp.485-489
• /
• 2000

생장이 우수한 인삼모상근 세포주 (KGHR-1, KGHR-5, KGHR-8) 및 6년생 인삼근의 부위별로 ginsenoside 양상 및 생성특성을 조사하였다. 인삼모상근 및 6년생 인상근에서 ginsenoslde-Rb$_1$, Rb$_2$, Rc, Rd, Re, Rf, Rg$_1$, Rg$_2$을 확인하였으며, 인삼모상근 세포주간 및 인삼근 부위별로 ginsenoside의 함량은 큰 차이를 나타내었다. 8종류의 ginsenoside함량이 가장 높은 인삼모상근은 KGHR-1 세포주로 17.42 mg/g dry wt와 함량을 나타내었다. 모상근세포주 KGHR-1은 ginsenoside-Rd, Rg$_1$을, KGHR-5는 ginsenoside-Rb$_1$, Rg$_1$을, 그리고 KGHR-8은 ginsenoside-Rd, Re을 상대적으로 많이 생성하는 특징을 지니고 있으며, ginsenoside-Rf의 생성은 매우 낮았다. 6년생 인삼근의 부위별 ginsenoside의 함량은 주근, 지근, 세근순으로 많았으며, 주근에서 ginsenoside-Rc의 생성은 ginsenoside의 50.99%로써 모상근 세포주의 4.90~6.89%보다 매우 높았다. 6년생 인삼근의 총 ginsenoside에 대한 ginsenoside-Rg$_1$의 비율은 3.43~14.18% 수준으로 주근, 지근, 세근순으로 급격히 감소하였으며, 모상관의 17.14~24.43%와 비교할 때 매우 낮은 수준을 나타내었다. 따라서 인삼모상근 배양을 통하여 특정 ginsenosides생산이 가능하리라 생각된다.

• Archives of Pharmacal Research
• /
• 제29권8호
• /
• pp.685-690
• /
• 2006

The effect of a main constituent ginsenoside Rg5 isolated from red ginseng and its metabolite ginsenoside Rh3 in a chronic dermatitis model was investigated. Ginsenosides Rg5 and Rh3 suppressed swelling of oxazolone-induced mouse ear contact dermatitis. These ginsenosides also reduced mRNA expressions of cyclooxygenase-2, interleukin $(IL)-1{\beta}$, tumor necrosis factor $(TNF)-{\alpha}$ and interferon $(IFN)-{\gamma}$. The inhibition of ginsenoside Rh3 was more potent than that of ginsenoside Rg5. These findings suggest that ginsenoside Rh3 metabolized from ginsenoside Rg5 may improve chronic dermatitis or psoriasis by the regulation of $IL-1{\beta}$ and $TNF-{\alpha}$ produced by macrophage cells and of $IFN-{\gamma}$ produced by Th cells.

• 한국수정란이식학회지
• /
• 제28권1호
• /
• pp.63-71
• /
• 2013

In this study, we used flow a cytometric assay to evaluate plasma membrane integrity and mitochondrial activity in post-thawed sperm that was supplemented with ginsenoside-$Rg_1$. Varying concentrations of ginsenoside-$Rg_1$ (0, 25, 50 and $100{\mu}M/ml$) were used in the extender during cryopreservation to protect the DNA of thawed sperm, thereby increasing the viability and motility rate as evaluated using a computer-assisted sperm analysis (CASA) method. The results derived from CASA were used to compare the fresh, control, and ginsenoside-$Rg_1$ groups. Sperm motility and the number of progressively motile sperm were significantly (p<0.05) higher in the $50{\mu}M/ml$ ginsenoside-Rg1 group ($61.0{\pm}4.65%$) than in the control ($46.6{\pm}7.02%$), $25{\mu}M/ml$ ($46.2{\pm}4.76%$), and $100{\mu}M/ml$ ginsenoside-$Rg_1$ ($52.0{\pm}1.90%$) groups. However, the velocity distribution of post-thawed sperm did not differ significantly. Membrane integrity and MMP staining as revealed using flow cytometry were significantly (p<0.05) higher ($91.6{\pm}0.82%$) in the $50{\mu}M/ml$ ginsenoside-$Rg_1$ group than in the other groups. Here, we report that ginsenoside-$Rg_1$ affects the motility and viability of boar spermatozoa. Moreover, ginsenoside-$Rg_1$ can be used as a protective additive for the suppression of intracellular mitochondrial oxidative stress caused by cryopreservation.

• Journal of Microbiology and Biotechnology
• /
• 제34권4호
• /
• pp.774-782
• /
• 2024

This study aimed to elucidate the anti-colon cancer mechanism of ginsenoside Rg1 in vitro and in vivo. Cell viability rate was detected using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tetrazolium assay. The inhibitory effect of ginsenoside Rg1 against CT26 cell proliferation gradually increased with increasing concentration. The in vivo experiments also demonstrated an antitumor effect. The monodansylcadaverine (MDC), transmission electron microscopy (TEM), and expression of autophagy marker proteins confirmed that ginsenoside Rg1 induced autophagy in vitro. Ginsenoside Rg1 induced autophagy death of CT26 cells, but this effect could be diminished by autophagy inhibitor (3-methyladenine, 3-MA). Additionally, in a xenograft model, immunohistochemical analysis of tumor tissues showed that the LC3 and Beclin-1 proteins were highly expressed in the tumors from the ginsenoside Rg1-treated nude mice, confirming that ginsenoside Rg1 also induced autophagy in vivo. Furthermoer, both in vivo and in vitro, the protein expressions of p-Akt, p-mTOR, and p-p70S6K were inhibited by ginsenoside Rg1, which was verified by Akt inhibitors. These results indicated that the mechanism of ginsenoside Rg1 against colon cancer was associated with autophagy through inhibition of the Akt/mTOR/p70S6K signaling pathway.

• 약학회지
• /
• 제25권2호
• /
• pp.43-47
• /
• 1981

In an attempt to obtain a saponin antigen, ginsenoside Rg$_{1}$ of Korean ginseng was condensed with bovine serum albumin through a series of modification in the side chain structure of ginsenoside Rg$_{1}$ to prepare a reactive intermediate $Rg_{1}$ azide. The modification of ginsenoside $Rg_{1}$[1] yielded $Rg_{1}$ decacetate [II], mp 252, $Rg_{1}$ acetate-glycol [III], mp 263, $Rg_{1}$ acetate-trisnoraldehyde [IV], mp 231, $Rg_{1}$ acetate-carboxylic acid [V], mp 282, $Rg_{1}$ acetate-methyl ester [VI], mp 271, $Rg_{1}$ hydrazide [VII], mp 220, and finally a reactive intermediate $Rg_{1}$ azide [VIII].

• 한국식품과학회지
• /
• 제35권3호
• /
• pp.536-539
• /
• 2003

백삼 가공품과 홍삼 가공품의 사포닌 분포 내용과 함량을 비교하기 위하여 시판되고 있는 백삼 농축액(WGC)과 홍삼 농축액(RGC)을 각각 1종 선정하여 조 사포닌의 함량과 개별 ginsenoside의 함량분포를 조사하였다. Shibata의 방법과 우리나라 식품공전에 따라 측정한 조 사포닌의 양은 WGC가 각각 10.65와 21.77%이었으며 RGC는 5.80와 10.94%이였고, HPLC에 의한 총 사포닌의 양은 WGC가 7.40와 10.64%, RGC는 3.31와 3.13%로서 백삼 농축액의 사포닌 함량이 홍삼 농축액의 경우 보다 전반적으로 높았다. HPLC로 분석한 인삼 사포닌, ginsenoside $Rb_1,\;Rb_2,\;Rc,\;Rd,\;Re,\;Rf,\;Rg_1,\;20(S)\;Rg_3,\;20(R)Rg_3,\;20(S)\;Rh_1$ 그리고 $20(R)\;Rh_1$ 이었으며 대부분 홍삼농축액 보다는 백삼농축액의 함량이 높았으며, 특히 ginsenoside $Rb_1,\;Rg_1$ 그리고 $Rb_2$은 백삼 농축액에 3배 이상 더 함유되어 있었다. 또한 protopanaxadiol group과 protopanaxatriol group의 비율(PD/PT)에 있어서는 농축액간의 차이는 크지 않았다. 홍삼의 특유 사포닌으로 알려진 20(S)- 및 20(R)-ginsenoside $Rg_3$가 WGC와 RGC에 비슷하게 분포하는 것으로 확인되었다. 20(S)-ginsenoside $Rg_3$의 조 사포닌 조제법에 따라 RGC에서 0.48과 0.47% WGC에 0.40와 0.53%, 20(R)-ginsenoside $Rg_3$도 RGC에 0.10과 0.11%, WGC에 0.14와 0.22%이었다.

• BMB Reports
• /
• 제56권10호
• /
• pp.551-556
• /
• 2023

Ginsenosides, among the most active components of ginseng, exhibit several therapeutic effects against cancer, diabetes, and other metabolic diseases. However, the molecular mechanism underlying the anti-osteoporotic activity of ginsenoside Rg2, a major ginsenoside, has not been clearly elucidated. This study aimed to determine the effects of ginsenoside Rg2 on receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation. Results indicate that ginsenoside Rg2 inhibits RANKL-induced osteoclast differentiation of bone marrow macrophages (BMMs) without cytotoxicity. Pretreatment with ginsenoside Rg2 significantly reduced the RANKL-induced gene expression of c-fos and nuclear factor of activated T-cells (Nfatc1), as well as osteoclast-specific markers tartrate-resistant acid phosphatase (TRAP, Acp5) and osteoclast-associated receptor (Oscar). Moreover, RANKL-induced phosphorylation of mitogen-activated protein kinases (MAPKs) was decreased by ginsenoside Rg2 in BMM. Therefore, we suggest that ginsenoside Rg2 suppresses RANKL-induced osteoclast differentiation through the regulation of MAPK signaling-mediated osteoclast markers and could be developed as a therapeutic drug for the prevention and treatment of osteoporosis.

• 대한화장품학회지
• /
• 제30권2호
• /
• pp.221-225
• /
• 2004

인삼(Panax ginseng C. A Meyer)의 뿌리는 전통적인 항-노화 및 항-주름제로 동양에서 사용되어 왔다. 그러나 인삼의 어떤 성분이 주름 형성을 억제하는데 효과적인지는 아직 밝혀지지 않았다. 최근 인삼의 주요 활성 성분으로 생각되는 ginsenosides가 20가지 이상 분리되었다. 이들 중 본 연구원들은 인삼에 의한 항-주름의 작용기작을 밝히기 위해 세포간질(extracellular matrix, ECM) 물질대사에 있어 ginsenoside Rg3의 진피에서의 효과를 시험하였다. 본 연구에서, ginsenoside Rg3의 항-주름 효과를 연구하기 위해 진피의 세포간질 구성 성분과 성장 인자를 ELISA (enzyme-1in14ed immunosorbent assay) 측정법으로 평가하였다. Ginsenoside Rg3은 human dermal fibroblasts 배양에서 type I procollagen과 fibronectin(FN) 생합성을 농도 증가에 비례하여 촉진시키고(p < 0.05, n=3), 농도에 비례하여 TGF-$\beta$1 수준을 증가 (p < 0.05, n=3) 시키는 것으로 밝혀졌다. RT-PCR 분석에서 AP-1 전사 인자(transcription factor)의 일부인 c-Jun의 mRNA 수준이 human dermal fibroblasts에서 ginsenoside Rg3에 의해 감소되었다. 이들 결과들은 ginsenoside Rg3이 fibroblasts에서 TGF-$\beta$1과 AP-1의 발현을 변화시킴으로써 type I collagen과 FN합성을 촉진시킴을 보여준다.

• Journal of Ginseng Research
• /
• 제47권6호
• /
• pp.784-794
• /
• 2023

Background: ginsenoside Rg5 is a rare ginsenoside with known hypoglycemic effects in diabetic mice. This study aimed to explore the effects of ginsenoside Rg5 on skin wound-healing in the Lepr^db/db mutant (db/db) mice (C57BL/KsJ background) model and the underlying mechanisms. Methods: Seven-week-old male C57BL/6J, SLC7A11-knockout (KO), the littermate wild-type (WT), and db/db mice were used for in vivo and ex vivo studies. Results: Ginsenoside Rg5 provided through oral gavage in db/db mice significantly alleviated the abundance of apoptotic cells in the wound areas and facilitated skin wound healing. 50 μM ginsenoside Rg5 treatment nearly doubled the efferocytotic capability of bone marrow-derived dendritic cells (BMDCs) from db/db mice. It also reduced NF-κB p65 and SLC7A11 expression in the wounded areas of db/db mice dose-dependently. Ginsenoside Rg5 physically interacted with SLC7A11 and suppressed the cystine uptake and glutamate secretion of BMDCs from db/db and SLC7A11-WT mice but not in BMDCs from SLC7A11-KO mice. In BMDCs and conventional type 1 dendritic cells (cDC1s), ginsenoside Rg5 reduced their glycose storage and enhanced anaerobic glycolysis. Glycogen phosphorylase inhibitor CP-91149 almost abolished the effect of ginsenoside Rg5 on promoting efferocytosis. Conclusion: ginsenoside Rg5 can suppress the expression of SLC7A11 and inhibit its activity via physical binding. These effects collectively alleviate the negative regulations of SLC7A11 on anaerobic glycolysis, which fuels the efferocytosis of dendritic cells. Therefore, ginsenoside Rg5 has a potential adjuvant therapeutic reagent to support patients with wound-healing problems, such as diabetic foot ulcers.